StreetAlpha.app
Home › Stocks › IMUX

Immunic, Inc. (IMUX)

Healthcare
$6.99
▼ −5.41%
LAST CLOSE · NOV 20

Immunic is a biotechnology company developing oral drugs for multiple sclerosis and gastrointestinal diseases. It last closed at $6.99 on Nov 20, down 5.41% on the day. The next earnings report for IMUX is expected around Thu, Feb 25, 2027. For the quarter ended Sep 2026, IMUX reported EPS of -$0.99. Over its last 8 reports the stock moved an average of 6.9% the session after earnings.

AI Auto Pilots
Is IMUX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold IMUX.

Key Stats

Last 12 months
Results
Net income
−$128.3M
Free cash flow
−$96.3M
Valuation
Market cap
$111.0M
15.9M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$132.0M
At Sep 30
Shareholder equity
$104.5M
Shares outstanding
15.9M
At Nov 6
Employees85 (Aug 1, 2024)
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$92.9M−$92.9MFY2021FY2022: −$120.4M−$120.4MFY2022FY2023: −$93.6M−$93.6MFY2023FY2024: −$100.5M−$100.5MFY2024FY2025: −$97.2M−$97.2MFY2025

From IMUX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · Time not announced
Reported EPS
-$0.99
Quarter ended Sep 2026
Year ago EPS
-$1.32
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.25Dec '24Mar 2025: -$2.51Mar '25Jun 2025: -$2.03Jun '25Sep 2025: -$1.32Sep '25Dec 2025: $4.83Dec '25Mar 2026: -$1.08Mar '26Jun 2026: -$0.80Jun '26Sep 2026: -$0.99Sep '26Latest -$0.99
Revenue by quarter
Not enough quarters on file yet.
How IMUX moved after its last 8 reports
Average move the session after a report ±6.9%
Nov 13, 2026Time not announced−3.5%
Aug 11, 2026Time not announced+9.8%
May 13, 2026Time not announced+8.8%
Feb 26, 2026Time not announced+4.1%
Nov 13, 2025Time not announced−6.2%
Aug 7, 2025Time not announced−7.9%
Nov 7, 2024Time not announced0.0%
Aug 8, 2024Time not announced+14.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on IMUXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on IMUX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on IMUX

Technical Analysis

IMUX · as of the Nov 20 close · updated each morning
Downtrend

The stock is 9% below its 20 day and 17% below its 50 day average. It is 66% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 39). The nearest support is the Pivot S1 at $6.79, and the nearest resistance the Pivot at $7.17.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 8.3%/day
Key levels
$17.4352 week high+149.4%
$11.59200 day average+65.8%
$11.46100 day average+63.9%
$8.22Swing high (Oct 29)+17.6%
$8.2050 day average+17.3%
$7.6020 day average+8.7%
$7.38Pivot R1+5.6%
$7.17Pivot+2.6%
$6.99Last close
$6.79Pivot S1−2.9%
$6.35Swing low (Oct 14)−9.2%
$5.0652 week low−27.6%
Indicators
RSI (14)38.64Weak, oversold below 30Neutral
MACD-0.28Above its signal lineBullish
Stochastic19.8Near the bottom of its rangeOversold
ADX (14)18.5No clear trend
Williams %R-98.6Oversold below −80, overbought above −20Oversold
CCI (20)-144.0Oversold below −100, overbought above 100Oversold
Rate of change−9.8%Change over 10 sessionsBearish
ATR (14)$0.58Typical daily range, 8.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IMUX

What happened before

See how IMUX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow IMUX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How IMUX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for IMUXHow many large options trades hit IMUX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

IMUX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲47 buying vs 18 selling
  • ▲Held by funds +14.1 pts
  • ▲Funds holding +23
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7956+41.1%
In funds' top 1020–
Held by funds68.8%54.7%+14.1 pts
New / increased28 / 1954 / 1−14.5%
Reduced / sold out11 / 71 / 76−76.6%
Put/call ratio0.090.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IMUX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

IMUX Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 13, 2025Duane NashExecutive ChairmanBuy20,000$0.83$17K
Jun 5, 2025Jason TardioPresident and COOBuy12,512$0.79$10K
Jun 5, 2025Joerg NeermannDirectorBuy100,000$0.77$77K
Jun 4, 2025Daniel VittCEO and DirectorBuy15,000$0.77$12K
Jun 3, 2025Richard Alan RudickDirectorBuy143,075$0.70$100K
Jun 3, 2025Glenn WhaleyCFOBuy45,000$0.71$32K
Every insider buy and sale for IMUX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See IMUX insider trades →

From SEC Form 4 filings by IMUX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMUX is in one of them and how their past IMUX trades turned out.

IMUX in the AI portfolios
Loading…

IMUX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IMUX in an article yet. Here's the latest on the wider market.

IMUX in the news

About Immunic

Immunic is a biotechnology company that develops oral drugs for neurologic and gastrointestinal diseases. Its lead candidate, vidofludimus calcium, is in Phase 3 testing for relapsing multiple sclerosis, and its IMU-856 candidate is being developed for conditions such as celiac disease and inflammatory bowel disease. The company has no products approved for sale yet and has not generated revenue from product sales. It is headquartered in New York, with its main research operations in Germany.

Headquarters
New York